UK-based CDMO Upperton Pharma Solutions has launched a nasal delivery development platform called UpperNose, the company said. The UpperNose services include pre-formulation analyses, dosage form selection, and formulation and process development through to clinical trial manufacturing.
Upperton Chief Scientific Officer Richard Johnson said, “The delivery of small molecules and biologics via the nose is one of the fastest growing sectors in the drug delivery field, but while the ability to self-administer drugs and vaccines is highly attractive, the specialist knowledge necessary to exploit this delivery route remains scarce. Meeting this demand, the UpperNose platform uses the knowledge and expertise of our experienced scientific team to support the efficient and timely development of molecules in both liquid and dry powder nasal formulations.”
Johnson added, “The UpperNose technology platform provides our customers with a progressive, data-driven approach to accelerate their nasal drug product development with the selection of the optimal dosage form with the best chances of success in the clinic and beyond. Working closely with our clients, we will quickly identify the most time and cost effective development program to facilitate early, smooth passage of our customer’s molecule from early-stage development into clinical trials.”
Read the Upperton Pharma Solutions press release.
